Primary Raynaud’s Syndrome: An Intrinsic Autoimmune Disease that Is Amenable to Mycophenolate Mofetil  

作　　者：Kamel El-Reshaid Shaima Al-Bader Kamel El-Reshaid;Shaima Al-Bader(Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait;Asad Al-Hamad Dermatology Center, Ministry of Health, Kuwait City, Kuwait)

机构地区：[1]Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait [2]Asad Al-Hamad Dermatology Center, Ministry of Health, Kuwait City, Kuwait

出　　处：《Case Reports in Clinical Medicine》2024年第11期485-489,共5页临床医学病理报告（英文）

摘　　要：Raynaud’s syndrome (RS) is a vasospastic disorder with potential hereditary predisposition and multiple triggering factors. After the exclusion of external stimuli and local disorders, autoimmunity presents a potential intrinsic trigger even in idiopathic RS. We present a 47-year-old woman with severe and progressive RS in both hands and toes for 2 years. She did not have: a) clinical and laboratory evidence of systemic autoimmune diseases;b) prior drug exposure;c) local digits disease. She could not tolerate vasodilators. Since she had elevated C-reactive protein, she received MMF as immunosuppressive therapy. Within 2 weeks, her symptoms improved, and she remained disease-free for 2 years. In conclusion, blocking intrinsic autoimmune triggers with MMF is a safe, practical, and effective short- and long-term treatment for refractory primary RS.Raynaud’s syndrome (RS) is a vasospastic disorder with potential hereditary predisposition and multiple triggering factors. After the exclusion of external stimuli and local disorders, autoimmunity presents a potential intrinsic trigger even in idiopathic RS. We present a 47-year-old woman with severe and progressive RS in both hands and toes for 2 years. She did not have: a) clinical and laboratory evidence of systemic autoimmune diseases;b) prior drug exposure;c) local digits disease. She could not tolerate vasodilators. Since she had elevated C-reactive protein, she received MMF as immunosuppressive therapy. Within 2 weeks, her symptoms improved, and she remained disease-free for 2 years. In conclusion, blocking intrinsic autoimmune triggers with MMF is a safe, practical, and effective short- and long-term treatment for refractory primary RS.

关 键 词：Raynaud’s Syndrome Mycophenolate Mofetil Treatment AUTOIMMUNE IDIOPATHIC 

分 类 号：R59[医药卫生—内科学]